Eli Lilly Receives Upgraded Price Target from Leerink; Announces Collaboration with BioArctic

Leerink upgraded Eli Lilly's (LLY) price target to $1,232 and maintained an Outperform rating. Additionally, LLY announced a collaboration agreement with BioArctic AB involving potential neurodegeneration treatments.

By Noor Ul Ain Rehman Sat, June 27, 2026 at 9:36 PM GMT+3 1 min read · Yahoo Finance · June 27, 2026, 18:36 UTC

Tickers: $LLY

Topics: Collaboration Agreements Pharmaceuticals Stock Analysis

Read the full article at Yahoo Finance

More World news

Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC